Publication: The first effect of COVID-19 pandemic on starting biological disease modifying anti-rheumatic drugs: Outcomes from the treasure real-life database
Date
Authors
Kanitez, Nilüfer Alpay
Kiraz, Sedat
Dalkılıç, Ediz
Kimyon, Gezmiş
Mercan, Rıdvan
Karadağ, Ömer
Beş, Cemal
Kılış, Levent
Akar, Servet
Ateş, Aşkın
Advisor
Language
Type
Publisher:
Aves
Journal Title
Journal ISSN
Volume Title
Abstract
Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.
Description
Source:
Keywords:
Keywords
Society classification criteria, Bath ankylosing-spondylitis, Spondyloarthritis, Reliability, Biological disease-modifying anti-rheumatic drug, Coronavirus disease 2019, Rheumatoid arthritis, Spondyloarthritis, Science & technology, Life sciences & biomedicine, Rheumatology
Citation
URI
https://doi.org/10.5152/eurjrheum.2022.21153
https://eurjrheumatol.org//en/the-first-effect-of-covid-19-pandemic-on-starting-biological-disease-modifying-anti-rheumatic-drugs-outcomes-from-the-treasure-real-life-database-133483
https://pmc.ncbi.nlm.nih.gov/articles/PMC10089133/
https://hdl.handle.net/11452/48751
https://eurjrheumatol.org//en/the-first-effect-of-covid-19-pandemic-on-starting-biological-disease-modifying-anti-rheumatic-drugs-outcomes-from-the-treasure-real-life-database-133483
https://pmc.ncbi.nlm.nih.gov/articles/PMC10089133/
https://hdl.handle.net/11452/48751